TD 0714

Drug Profile

TD 0714

Alternative Names: TD0714

Latest Information Update: 28 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance Biopharma
  • Class Antihypertensives; Cardiovascular therapies
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cardiovascular disorders; Kidney disorders

Most Recent Events

  • 25 Oct 2016 Pharmacokinetics and adverse events data from a phase I multi-ascending dose trial in Kidney disorders and Cardiovascular disorders released by Theravance
  • 25 Oct 2016 Theravance Biopharma plans a phase I trial for Cardiovascular disorders (IV)
  • 09 Mar 2016 Pharmacokinetics and adverse events data from a phase I trial in Kidney disorders and Cardiovascular disorders released by Theravance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top